PriceTargets.com logo

Nektar Therapeutics - NKTR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 642.57%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$0.61 As of 05/7/2025 04:59 PM ET
▼ -0.036 (-5.61%)

This chart shows the closing price for NKTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarAprMay$0.64Closing price on 05/06/25:
Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

Analyst Price Target is $4.50
▲ +642.57% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $4.50, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 642.57% upside from the last price of $0.61.

This chart shows the closing price for NKTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
5/248/2411/241/255/255/26$0.34$2.01$3.67$5.34$7Closing price on 05/06/25: $0.64High$7.00Average$4.50Low$2.00




Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Nektar Therapeutics. This rating has held steady since February 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/14/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
2/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/11/2025Jefferies Financial GroupUpgradeHold ➝ Buy$1.00 ➝ $2.00
3/14/2025OppenheimerUpgradeMarket Perform ➝ Outperform$6.00
3/13/2025William BlairReiterated RatingMarket Perform
3/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
2/25/2025William BlairReiterated RatingMarket Perform
2/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
1/8/2025B. RileyInitiated CoverageBuy$4.00
1/7/2025B. RileyUpgradeStrong-Buy
12/10/2024HC WainwrightInitiated CoverageBuy$6.50
11/4/2024Piper SandlerInitiated CoverageOverweight$7.00
9/30/2024BTIG ResearchReiterated RatingBuy$4.00
6/28/2024Rodman & RenshawInitiated CoverageBuy$2.00
3/6/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$0.50 ➝ $1.00
3/5/2024William BlairReiterated RatingMarket Perform
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweight
11/9/2023TD CowenUpgradeMarket Perform ➝ Outperform
8/7/2023MizuhoReiterated RatingNeutral$6.00
5/10/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$1.50 ➝ $1.00
3/6/2023OppenheimerLower TargetMarket Perform$5.00 ➝ $3.00
2/27/2023The Goldman Sachs GroupLower TargetSell$3.00 ➝ $2.00
2/24/2023SVB SecuritiesLower Target$5.00 ➝ $3.00
2/24/2023Leerink PartnersLower TargetMarket Perform$5.00 ➝ $3.00
2/24/2023Jefferies Financial GroupDowngradeHold ➝ Underperform$3.20 ➝ $1.50
8/8/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
4/20/2022OppenheimerDowngradeOutperform ➝ Market Perform
4/18/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$3.00
4/18/2022Leerink PartnersLower TargetMarket Perform$7.00 ➝ $6.00
4/18/2022MizuhoLower TargetNeutral$8.00 ➝ $6.00
3/16/2022Canaccord Genuity GroupLower TargetBuy$25.00 ➝ $6.00
3/15/2022Leerink PartnersLower TargetMarket Perform$18.00 ➝ $7.00
3/15/2022MizuhoDowngradeBuy ➝ Neutral$35.00 ➝ $8.00
3/14/2022CowenDowngradeOutperform ➝ Market Perform$35.00 ➝ $8.00
3/14/2022OppenheimerDowngradeOutperform ➝ Market Perform
3/14/2022Stifel NicolausDowngradeBuy ➝ Hold$24.00 ➝ $5.00
3/14/2022BTIG ResearchDowngradeBuy ➝ Neutral
3/14/2022William BlairDowngradeOutperform ➝ Market Perform
3/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$18.00 ➝ $6.00
3/9/2022OppenheimerUpgradeMarket Perform ➝ Outperform$21.00
3/1/2022JPMorgan Chase & Co.Lower Target$24.00 ➝ $17.00
11/8/2021BTIG ResearchLower TargetPositive ➝ Buy$80.00 ➝ $54.00
11/8/2021Leerink PartnersLower TargetMarket Perform$19.00 ➝ $18.00
11/8/2021BenchmarkUpgradeHold ➝ Buy$20.00
11/5/2021OppenheimerLower TargetMarket Perform$25.00 ➝ $21.00
9/10/2021Bank of AmericaInitiated CoverageNeutral$18.00
8/6/2021Leerink PartnersLower TargetMarket Perform$20.00 ➝ $19.00
6/28/2021Stifel NicolausUpgradeHold ➝ Buy$22.00 ➝ $24.00
5/10/2021Leerink PartnersLower TargetMarket Perform$21.00 ➝ $20.00
5/7/2021MizuhoReiterated RatingBuy
4/6/2021Leerink PartnersBoost TargetMarket Perform$20.00 ➝ $21.00
3/1/2021BenchmarkReiterated RatingBuy ➝ Hold$26.00
2/22/2021BenchmarkDowngradeBuy ➝ Hold$26.00
1/5/2021Stifel NicolausInitiated CoverageHold$18.00
11/12/2020Leerink PartnersBoost TargetMarket Perform$17.00 ➝ $20.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral$26.00
8/14/2020Leerink PartnersLower TargetMarket Perform$18.00 ➝ $17.00
8/7/2020OppenheimerReiterated RatingHold$25.00
6/10/2020CfraDowngradeHold ➝ Sell
5/26/2020MizuhoInitiated CoverageBuy$35.00
5/18/2020OppenheimerBoost TargetMarket Perform$24.00 ➝ $25.00
5/12/2020HC WainwrightLower TargetNeutral$32.00 ➝ $26.00
5/8/2020Leerink PartnersBoost TargetMarket Perform$17.00 ➝ $18.00
(Data available from 5/7/2020 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/9/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/8/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/7/2025
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2025
  • 9 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2025
  • 8 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/7/2025
  • 8 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2025

Current Sentiment

  • 8 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nektar Therapeutics logo
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $0.61
Low: $0.59
High: $0.64

50 Day Range

MA: $0.72
Low: $0.49
High: $0.91

52 Week Range

Now: $0.61
Low: $0.43
High: $1.93

Volume

2,827,098 shs

Average Volume

1,825,190 shs

Market Capitalization

$112.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: B. Riley, BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Piper Sandler, Rodman & Renshaw, StockNews.com, and William Blair.
View the latest analyst ratings for NKTR.

What is the current price target for Nektar Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 642.6%. Piper Sandler has the highest price target set, predicting NKTR will reach $7.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.

What is the current consensus analyst rating for Nektar Therapeutics?

Nektar Therapeutics currently has 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTR will outperform the market and that investors should add to their positions of Nektar Therapeutics.
View the latest ratings for NKTR.

What other companies compete with Nektar Therapeutics?

Other companies that are similar to Nektar Therapeutics include Omeros, Assembly Biosciences, Cumberland Pharmaceuticals, Eli Lilly and Company and Johnson & Johnson. Learn More about companies similar to Nektar Therapeutics.

How do I contact Nektar Therapeutics' investor relations team?

Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 482-5300 and its investor relations email address is investors@nektar.com. The official website for Nektar Therapeutics is www.nektar.com. Learn More about contacing Nektar Therapeutics investor relations.





Receive Nektar Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Nektar Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.